Терапия » АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ: ДИАГНОСТИКА, ОБЩИЕ ПРИНЦИПЫ ЛЕЧЕНИЯ И МЕДИКАМЕНТОЗНАЯ ТЕРАПИЯ У КОМОРБИДНЫХ ПАЦИЕНТОВ

АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ: ДИАГНОСТИКА, ОБЩИЕ ПРИНЦИПЫ ЛЕЧЕНИЯ И МЕДИКАМЕНТОЗНАЯ ТЕРАПИЯ У КОМОРБИДНЫХ ПАЦИЕНТОВ

DOI: https://dx.doi.org/10.18565/therapy.2023.9suppl.88-109

Базовая структура инфографики соответствует следующим источникам:
Клинические рекомендации. Артериальная гипертензия у взрослых.
Российское кардиологическое общество. Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 62. Доступ: https://cr.minzdrav.gov.ru/schema/62_2
Адаптировано и переработано со ссылками на использованную литературу
Для цитирования: Артериальная гипертензия: диагностика, общие принципы лечения и медикаментозная терапия у коморбидных пациентов.
Алгоритмы диагностики и лечения. Терапия. 2023; 9 (9S): 88–109.

Полный текст статьи доступен
в "Библиотеке Врача"

Литература

1. Клинические рекомендации. Артериальная гипертензия у взрослых. Российское кардиологическое общество. Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 62. Доступ: https://cr.minzdrav.gov.ru/schema/62_2 (дата обращения – 01.10.2023).

2. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36(10): 1953–2041. https://dx.doi.org/10.1097/HJH.0000000000001940.

3. Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360:1903–13.

4. Chester E.M., Agamanolis D.P., Banker B.Q., Victor M. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. Neurology 1978; 28: 928–39.

5. Cremer A., Amraoui F., Lip G.Y. et al. From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens. 2016; 30: 463–66. https://dx.doi.org/10.1038/jhh.2015.112.

6. Grassi D., O’Flaherty M., Pellizzari M. et al. Hypertensive urgencies in the emergency department: evaluating blood pressure response to rest and to antihypertensive drugs with different profiles. J Clin Hypertens (Greenwich). 2008; 10: 662–67. https://dx.doi.org/10.1111/j.1751-7176.2008.00001.x.

7. Dickinson H.O., Mason J.M., Nicolson D.J. et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006; 24: 215–33.

8. Lim S.S., Vos T., Flaxman A.D. et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2224–60. https://dx.doi.org/10.1016/S0140-6736(12)61766-8.

9. Государственный реестр лекарственных средств Минздрава России. Доступ: http://grls. rosminzdrav.ru (дата обращения – 01.10.2023).

10. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens. 2015; 33: 1321–41. https://dx.doi.org/10.1097/HJH.0000000000000614.

11. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressurelowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens. 2016; 34: 1921–32. https://dx.doi.org/10.1097/HJH.0000000000001052.

12. Kronish I.M., Woodward M., Sergie Z. et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011; 123: 1611–21. doi: 10.1161/CIRCULATIONAHA.110.983874.

13. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017; 35: 2150–60. https://dx.doi.org/10.1097/HJH.0000000000001547.

14. Ettehad D., Emdin C.A., Kiran A. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387: 957–67. https://dx.doi.org/10.1016/S0140-6736(15)01225-8.

15. Barrios V., Navarro A., Esteras A. et al.; ; Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad). Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press. 2002; 11(2): 95–100. https://dx.doi.org/10.1080/08037050211265.

16. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens. 2015; 33: 195–211. https://dx.doi.org/10.1097/HJH.0000000000000447.

17. Rimoldi S.F., Messerli F.H., Chavez P. et al. Efficacy and safety of calcium channel blocker/ diuretics combination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens (Greenwich). 2015; 17(3): 193–99. https://dx.doi.org/10.1111/jch.12462.

18. Gupta P., Patel P., Strauch B. et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017; 70: 1042–48. https://dx.doi.org/10.1161/HYPERTENSIONAHA.117.09631.

К содержанию номера